3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On September 17, 2026, Angel Studios entered into a Second Amended and Restated merger agreement for its acquisition of Toothy Cow Productions, which revises how Class A Common Stock is allocated among TCP's unitholders. The filing says the net effect is to shift part of the consideration from TCP Common Units to TCP Preferred Units, and that Company related parties, who own 2.3% of TCP units, will also receive shares.
Agreement dated September 17, 2026, amends and restates the June 29, 2026 A&R TCP Merger Agreement in its entirety.
Preferred Reallocation Shares set at 439,127 shares of Buyer Common Stock; Incentive Shares reduced from 516,620 to 77,493 shares.
Company committed up to $11.9 million to fund TCP operations through seasons three and four; $12.6 million provided to date.
If the acquisition is not completed, operational funding converts into TCP Class B Preferred Units at $1.50 per unit plus warrants.
Pyxis Oncology closed an underwritten public offering on October 1, 2026, selling 36,047,919 shares and pre-funded warrants for 1,883,121 shares, each paired with common warrants, for a combined price of $2.90 per share. The company expects net proceeds of about $102.8 million, and says its cash plus these proceeds will fund operations into the first half of 2028. The common warrants cannot be exercised until stockholders approve an increase in authorized shares, and if they are exercised, the company would receive about $162.2 million more, net of a 6% solicitation fee.
Offering: 36,047,919 shares and 1,883,121 pre-funded warrants, with common warrants for up to 49,310,352 shares; closed October 1, 2026
Combined public offering price of $2.90 per share; common warrants have a $3.50 exercise price
Net proceeds of about $102.8 million; up to about $162.2 million more if all warrants are exercised, net of a 6% fee
Warrants require a stockholder vote to increase authorized shares, with a meeting planned within 60 days of closing; the company says funds may be insufficient for the Phase 3 Headliner trial if warrants go unexercised
Synaptics and onsemi signed an amended and restated merger agreement on October 1, 2026, after an unsolicited competing proposal received September 2, 2026. Synaptics shareholders would receive $123 per share in cash instead of onsemi stock, and the Synaptics board unanimously approved the revised deal. The transaction is expected to close by mid-2027, subject to Synaptics shareholder approval and regulatory approvals.
Merger consideration is $123 per share in cash, without interest; the deal is valued at approximately $5.7 billion, compared with approximately $7 billion under the prior agreement.
The transaction is expected to close by mid-2027, subject to Synaptics shareholder approval, required regulatory approvals and other customary conditions.
The Federal Trade Commission has approved the transaction, and regulators in other jurisdictions are reviewing it; the Hart-Scott-Rodino approval has already been obtained.
onsemi will fund the deal with cash on hand and committed debt financing from Morgan Stanley, and the agreement has no financing condition.
ENDRA Life Sciences amended its June 25, 2026 merger agreement with ASP Isotopes and related parties on October 1, 2026, removing the classified board requirement, revising the minimum cash closing condition to $3,800,002.59 less agreed expenses, and allowing ASP-related lending to Renergen to rise from $80 million to up to $200 million. The company also amended warrants held by an ASP Isotopes affiliate to remove the 4.99% beneficial ownership limit, which changes how that affiliate can exercise them.
Amendment dated October 1, 2026 changes the merger terms, including the minimum cash closing condition of $3,800,002.59, less agreed expenses.
Renergen's ASPI borrowing capacity would rise from $80 million to up to $120 million, then to up to $200 million at or before closing.
Warrant amendments remove the 4.99% beneficial ownership limitation for LHE LNG Holdings, an ASP Isotopes subsidiary.
Warrants covering 324,372 pre-funded shares and all common warrants become exercisable only after stockholder approval.
onsemi, Synaptics and Merger Sub signed an Amended and Restated Merger Agreement on October 1, 2026, after Synaptics received an unsolicited proposal from a third party. The revised deal is all-cash at $123 per share, with an aggregate value of about $5.7 billion versus about $7 billion under the prior agreement. onsemi says the transaction is now expected to be immediately accretive to non-GAAP earnings per share upon closing.
Merger consideration revised to $123 per share in cash; aggregate value about $5.7 billion, down from about $7 billion under the June 25, 2026 agreement.
Morgan Stanley Senior Funding, Inc. committed up to $2.45 billion of senior secured term loan under a commitment letter dated October 1, 2026.
onsemi expects the deal to be immediately accretive to non-GAAP EPS; the transaction is expected to close by mid-2027, subject to Synaptics shareholder approval and regulatory approvals.
The Federal Trade Commission has approved the transaction; regulators in other jurisdictions are still reviewing it.
Nexalin Technology received Nasdaq confirmation on September 30, 2026 that it has regained compliance with the $1.00 minimum bid price requirement. The company still must show at least $2,500,000 in stockholders' equity by January 4, 2027, or its stock faces delisting from Nasdaq.
Nasdaq confirmed on September 30, 2026 that the bid price requirement of $1.00 per share is met
Remaining condition: stockholders' equity of at least $2,500,000 by January 4, 2027
The company says it intends to meet the equity requirement, but gives no assurance it will
Two indirect subsidiaries of SharonAI Holdings signed a $356 million senior secured term loan facility on September 28, 2026, to finance GPU servers and data center infrastructure for a customer contract. The parent company guarantees the loans on a limited, releasable basis, and the filing says the financing becomes non-recourse to the parent after Facility A is repaid. Shareholders should note the debt carries fixed interest rates of 7.25% to 9.95% and a 42-month maturity, with a change of control and customer contract default treated as review events.
Facilities total up to US$356 million: Facility A up to US$150 million and Facility B up to US$206 million.
Facility A bears an initial 7.25% fixed rate that rises to as high as 9.95%; Facility B bears a fixed 9.95% rate.
Each facility matures 42 months after first utilization, and the Company guarantees the Borrowers' payment obligations through a releasable guarantee deed poll.
The press release says Jarden Australia was sole financial advisor and arranger, and names Goldman Sachs among the investors.
Modine completed the spin-off and combination of its Performance Technologies business with Gentherm in a Reverse Morris Trust transaction on October 1, 2026. Modine received a cash distribution of approximately $156 million, used to repay debt, and shareholders received 0.44619 Gentherm shares per Modine share, with Modine shareholders owning about 43.62% of the combined company.
Modine received a cash distribution of approximately $156 million, used to prepay borrowings under its credit agreement with JPMorgan Chase Bank, N.A. as administrative agent.
Modine shareholders received 0.44619 Gentherm shares for each Modine share held at the close of business on September 28, 2026.
The transaction valued the Performance Technologies business at approximately $946.4 million, based on Gentherm's closing price on September 30, 2026.
Modine plans a special shareholder meeting within three months to vote on renaming the company Modexus Solutions; the ticker MOD is expected to remain unchanged.
Achieve Life Sciences said its board appointed Benjamin Halladay as Chief Financial Officer effective October 5, 2026, replacing Mark Oki, who is stepping down from the role on the same date. Mr. Halladay previously served as CFO of Esperion Therapeutics from November 2022 until September 2026, and the company said Mr. Oki's departure is not related to any disagreement over its financial statements or disclosures.
Benjamin Halladay appointed CFO and principal financial officer, effective October 5, 2026
Mark Oki steps down as CFO effective October 5, 2026; the company says there was no disagreement over financial statements or disclosures
Halladay offer letter includes $525,000 base salary, bonus of up to 40% of base salary, option for up to 200,000 shares and 200,000 restricted stock units
Full employment agreement text to be filed with the Form 10-Q for the quarter ending September 30, 2026
Gentherm completed its combination with Modine's Performance Technologies business on October 1, 2026, in a Reverse Morris Trust transaction. Modine shareholders own about 43.62% of the combined company, and Gentherm shareholders own about 56.38%. The filing also discloses a $250.0 million term loan, guaranteed by Gentherm and secured by substantially all of its assets, plus a $2.07 per share special dividend payable October 7, 2026.
Modine shareholders received 0.44619 Gentherm shares for each Modine share held at the September 28, 2026 record date, with cash in lieu of fractional shares.
Gentherm declared a special dividend of $2.07 per share, payable October 7, 2026 to shareholders of record as of September 28, 2026.
SpinCo borrowed $250.0 million of term loans under a senior secured delayed draw facility with Bank of America, N.A. as administrative agent; Gentherm guarantees the obligations.
Paul Mascarenas was appointed to the board effective October 1, 2026, increasing its size from 9 to 10 members; Katrin Schatz was named Interim President of Modine Performance Technologies.
On October 1, 2026, subsidiary 5E SVM completed its purchase of real property, production facilities, brine resources and other assets from Searles Valley Minerals and related sellers. Consideration included about $3.4 million in cash, 8.3 million common shares and a $6.2 million promissory note, and 5E SVM also took a $10.0 million senior secured bridge loan from Karnavati Holdings, of which $7.0 million was funded at closing. The deal adds assets and debt and increases the share count, which shareholders will want to track.
Consideration: about $3.4 million cash (including a prior deposit), 8.3 million common shares (including 312,500 shares due later upon conditions) and a $6.2 million senior unsecured promissory note.
Promissory note accrues 14.5% annual interest, paid in kind; requires a cash payment of about $1.2 million at the 24-month anniversary and matures on the fifth anniversary.
$10.0 million senior secured bridge facility with Karnavati Holdings, 8.00% interest paid in kind, $7.0 million funded at closing, matures 270 days after closing with a $1.0 million fee.
Shares outstanding after closing: 49,634,871. Company expects $15.7 million cash as of September 30, 2026; the filing gives post-transaction cash as $19.6 with no unit, and Q3 results are preliminary.
On September 29, 2026, Akari Therapeutics amended the Chief Executive Officer Agreement with CEO Abizer Gaslightwala. The amendment raises his base salary from $475,000 to $625,000 effective August 18, 2026, increases his target bonus to 55% of base salary, and grants options on 174,000 ADSs, with parts of the package tied to shareholder approval of a plan amendment.
Base salary rises from $475,000 to $625,000, effective August 18, 2026; $62,500 of it is delivered as RSUs instead of cash over 12 months
Target annual bonus increases from 50% to 55% of base salary, for target base salary and bonus of approximately $970,000
Options to purchase 174,000 ADSs granted as of August 18, 2026, vesting monthly over four years from March 18, 2026
RSUs and option grants depend on shareholder approval of an increase to the ADSs reserved under the 2023 Plan
National Bank Holdings said its bank subsidiary expects material impairments on specific commercial loans, mainly in the franchise and healthcare industries, plus a $4.0 million impairment on a FinTech partnership investment. The charges are expected to reduce after-tax earnings by $32.0 million to $34.0 million, or $0.72 to $0.76 per diluted share, for the third quarter and nine months ended September 30, 2026. Separately, the board approved an additional $40.1 million share repurchase authorization, bringing total repurchase authority to $100.0 million.
Loans with $65.0 million aggregate outstanding principal will be reserved or charged down to an estimated $18.2 million, with estimated charge-offs of $46.8 million.
Provision expense is expected to be $38.0 million to $40.0 million for the three months ended September 30, 2026.
A $4.0 million impairment on one FinTech partnership investment will reduce non-interest income for the quarter.
On September 30, 2026, the board approved a $40.1 million buyback, bringing total authority to $100.0 million; 44,285,618 Class A shares were outstanding at quarter end.
Accelevation Holdings Corp. completed its initial public offering of Class A common stock, with the company selling 10,000,000 shares and selling stockholders selling 20,000,000 shares at $18.00 per share, closing on October 1, 2026. The filing also reports seven new directors, amended charter and bylaws, and new agreements governing the company's structure, which shape how existing owners and new public shareholders are related.
Firm offering: 10,000,000 shares sold by the company and 20,000,000 by selling stockholders at $18.00 per share; underwriters hold a 30-day option for up to 4,500,000 more shares
Seven directors appointed September 29, 2026, including Manu Bettegowda, Matt Bujor and Michael Rubiera-linked director nomination rights
Amended and restated certificate of incorporation and bylaws effective September 29, 2026; 116,965,529 Class B shares issued to Investment Holdings
Cardinal Infrastructure Group completed its acquisition of Allied Paving Contractors on October 1, 2026, for approximately $115.0 million, paid in cash and 1,006,796 newly issued Class A shares, subject to customary post-closing adjustments. The deal expands Cardinal's self-performed paving work in the Atlanta market, and Allied generated approximately $100 million in standalone revenue, though part of that volume will be performed on Cardinal projects and reflected in margin rather than consolidated revenue. Shareholders will see the share issuance dilute their holdings slightly, and the filing gives no profit or earnings figures for Allied.
Acquisition of Allied Paving Contractors closed October 1, 2026, for approximately $115.0 million in total consideration
Consideration included approximately $88.9 in cash and 1,006,796 Class A Common Stock shares, issued without registration under Section 4(a)(2)
Allied generated approximately $100 million in revenue on a standalone basis
Allied CEO John McLean will join Cardinal's leadership team to manage paving operations across Georgia
H2O America said its Texas subsidiary completed the purchase of substantially all assets of Quadvest's water and sewer utility businesses on October 1, 2026, for a base price of $540 million, subject to customary adjustments. The company says the deal more than doubles its Texas water and wastewater connections and expects Texas to represent 26% of its customer base by 2029, up from 8%.
Base purchase price of $540 million, subject to customary purchase price adjustments
Deal covers the regulated and wholesale water and sewer businesses of Quadvest, with closing on October 1, 2026
H2O America expects Texas to be 26% of its customer base by 2029, versus 8% before October 1
Financial statements and pro forma information will be filed by amendment later
OpenText issued $1.0 billion of senior secured notes due 2031 and 2033 on October 1, 2026, and extended its revolving credit facility maturity from December 19, 2028 to October 1, 2031. Proceeds, with cash on hand, are earmarked to redeem its $1.0 billion 6.900% notes due 2027 and to fund a tender offer for up to $300 million of its 3.875% notes due 2028, with settlement expected October 2, 2026.
Two $500 million note tranches: 6.700% due October 15, 2031 and 7.150% due October 15, 2033
Proceeds plus cash on hand to redeem all $1.0 billion of 6.900% senior secured notes due 2027
Tender offer for up to $300 million of 3.875% senior notes due 2028; both transactions expected to settle October 2, 2026
Revolver maturity extended from December 19, 2028 to October 1, 2031
Solaris Energy Infrastructure issued $1.25 billion of 7.000% senior notes due 2032 in a private placement on October 1, 2026, with net proceeds of about $1,227.2 million. The company also raised its revolving credit facility commitments by $200.0 million to $850.0 million. The new debt adds to the company's borrowings, and the filing says proceeds are for general corporate purposes, growth capital expenditures and offering fees.
$1.25 billion of 7.000% senior notes due April 1, 2032, issued October 1, 2026
Net proceeds of approximately $1,227.2 million after initial purchasers' discount and estimated expenses
Revolving credit facility commitments increased from $650.0 million to $850.0 million; letter of credit sublimit raised to $325.0 million
Notes are senior unsecured guarantees by the parent and subsidiary guarantors; redemption at 103.500% from April 1, 2029 at the earliest
Gaxos.ai Inc. was notified on September 28, 2026 by Nasdaq that its common stock is not meeting the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market. The notice has no immediate effect on trading, and the company has until March 29, 2027 to regain compliance, with a possible second 180-day period and a reverse stock split under consideration.
Notice dated September 28, 2026, based on closing bid prices from August 14, 2026 to September 25, 2026
Compliance period ends March 29, 2027; stock must close at or above $1.00 for at least 10 consecutive business days
If not compliant, a second 180-day period may be available; otherwise Nasdaq would issue a delisting determination with a right to appeal to a Hearings Panel
Company may consider a reverse stock split; shares continue to trade as GXAI
NIKE reported fiscal first-quarter 2027 revenue of $11.2 billion, down 4%, and diluted EPS of $0.48 versus $0.49 a year earlier. The company also announced the Pace multi-year program, with about $1.0 billion of expected pre-tax charges and about $2.5 billion of cumulative savings through fiscal 2031, and guided to a high-single-digit revenue decline for fiscal 2027.
Q1 revenue $11.2 billion, down 4% reported and 5% currency-neutral; net income $0.7 billion, down 2%
Pace expected pre-tax charges of about $1.0 billion, plus about $0.3 billion of severance already recognized in fiscal 2026
Pace expected to deliver about $2.5 billion in cumulative savings through fiscal 2031, before charges and reinvestment
Fiscal 2027 outlook: revenues to decline high-single digits; adjusted diluted EPS $1.15 to $1.35
Liquidity Services completed its acquisition of Auction Holdings, Inc., which operates the Invaluable, AuctionZip and RFC Auction Systems online marketplaces, for a base purchase price of $80 million in cash funded with cash on hand. The company expects the deal to be accretive to GAAP and Non-GAAP Adjusted Diluted EPS in fiscal 2027, but it did not provide a reconciliation and said acquisition-related items could materially affect GAAP results. The filing does not report financial results for the acquired businesses beyond their gross merchandise sales for fiscal 2025.
Base purchase price of $80 million in cash, on a debt-free, cash-free basis, subject to customary adjustments, funded with cash on hand
$9.4 million of cash consideration deposited in escrow for indemnification and downward purchase-price adjustments, with portions scheduled for release after 12 months and three years
Company expects accretion to GAAP and Non-GAAP Adjusted Diluted EPS in fiscal 2027, without a GAAP reconciliation
Acquired businesses processed more than $500 million of gross merchandise sales for the fiscal year ended December 31, 2025, and Invaluable's leadership is expected to remain
Paramount Skydance appointed Ynon Kreiz, Mattel's Chairman and CEO, as Co-Chief Executive Officer and a board member, effective October 5, 2026, and the company says he will oversee day-to-day operations and integration of the combined businesses after its pending Warner Bros. Discovery merger. The filing also sets out his pay, equity awards and severance terms, and the merger is expected to close on October 6, 2026.
Base salary of at least $3,500,000, rising to $5,000,000 after the Warner Bros. Discovery closing; target bonus of $1,500,000, rising to $4,900,000.
Signing award of 2,625,000 fully vested RSUs and pre-closing award of 1,250,000 RSUs covering Class B common stock.
Annual equity awards of $15,000,000, rising to $20,100,000 after the Warner Bros. Discovery closing.
Qualifying termination severance equal to two times base salary plus target bonus, paid over 24 months. Expected Warner Bros. Discovery closing date is October 6, 2026, with WBD holders to receive $31.01666668 per share in cash if closing o
Lantern Pharma received a Nasdaq notice on September 25, 2026 saying it is out of compliance with the minimum market value of listed securities requirement of $35 million over the last 30 consecutive business days. The company has until March 24, 2027 to regain compliance, or it expects Nasdaq could begin delisting proceedings from the Nasdaq Capital Market.
Nasdaq notice dated September 25, 2026 cites Listing Rule 5550(b)(2) with a $35 million minimum market value requirement
Nasdaq also said the company does not meet Listing Rules 5550(b)(1) and 5550(b)(3)
Compliance period runs 180 calendar days, ending March 24, 2027
Regaining compliance requires a market value of at least $35 million for 10 consecutive business days
SINTX Technologies said preliminary, unaudited third-quarter 2026 revenue was $2.2 million, above the high end of its previous $0.9 million to $1.1 million guidance, with about $2.1 million from product sales. The company also plans to send a call notice to holders of its Class B Warrants, which could bring up to $4.0 million in cash if fully exercised, though exercise is not assured and the figures may change after the quarter-end close.
Preliminary Q3 2026 revenue of $2.2 million, versus prior guidance of $0.9 million to $1.1 million
Revenue was about $2.1 million from product sales; the company said the quarter's sales were mainly industrial parts sold to aerospace subsidiaries of Fortune 500 companies
Class B Warrant call notice covers about 1.88 million shares, with up to $4.0 million in potential proceeds if fully exercised
Company reiterated its fourth-quarter 2026 revenue guidance range from its last earnings call; final results may differ from the preliminary figures
La Rosa Holdings Corp. (Nasdaq: LRHC) acquired NVIDIA B300 GPUs, leased them back under a long-term arrangement, and said it will evaluate strategic alternatives for its real estate operations, including a potential divestiture. The filing also issues Series F preferred stock in several transactions with conversion into common stock, which could dilute shareholders, and names Nicholas Adler CEO effective October 1, 2026. The filing is from La Rosa Holdings Corp., not Stratum Holdings Corp. (SRTM) as named in the request.
Sept. 28, 2026 Exchange Agreement: holders exchanged $1,500,000 of an $11,000,000 senior secured convertible note, plus all Series C, D and E preferred shares, for 3,410 Series F preferred shares.
Sept. 30, 2026 Settlement Agreement: 500 Series F shares issued for $5,688,263 in outstanding tokens; 5,500 more are due if conditions are met.
Sept. 30, 2026 Contribution and Purchase Agreement: 3,000 Series F shares issued for contributed GPUs; 4,000 more are due after $350,000 of gross rental income, and up to 25,000 additional shares may be issued.
Nicholas Adler became CEO and interim CFO effective October 1, 2026; founder Joe La Rosa stepped down as CEO and remains a director.
Vir Biotechnology appointed Aziz Sawaf, formerly CFO of Theravance Biopharma, as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Brent Sabatini, who has been interim principal financial officer, will stop serving in that role and remain Senior Vice President and Chief Accounting Officer.
Sawaf's annualized base salary is $520,000, with a target bonus of 45% of base salary and a one-time cash sign-on bonus of $150,000.
Sawaf's offer includes an option to buy 150,000 shares and 75,000 restricted stock units, granted on or around November 15, 2026.
Under the Severance Plan, a covered termination after a change in control yields a lump sum of 12 months' base salary plus target bonus, while one outside that period yields nine months' base salary plus a pro-rated bonus.
Omega Healthcare Investors appointed Matthew P. Gourmand, its President, as President and Chief Executive Officer effective October 1, 2026, succeeding C. Taylor Pickett, who is retiring. Gourmand was also appointed to the Board to fill the seat vacated by Pickett's retirement, with the term expiring in 2027. The filing says Pickett's retirement involved no disagreement with the company on its operations, policies or practices.
Matthew P. Gourmand, age 51, becomes CEO and director effective October 1, 2026
He succeeds C. Taylor Pickett, who retires as CEO and from the Board
Gourmand has served as President since January 1, 2025 and previously led corporate strategy and investor relations
Board size remains at eight; the Board does not expect to name Gourmand to any committees
On October 1, 2026, Corteva completed its separation into two public companies by distributing all outstanding Vylor Inc. shares to Corteva common stockholders of record as of September 24, 2026. Vylor is expected to begin regular-way trading on the New York Stock Exchange under the symbol VYLR on October 1, 2026. The filing does not report financial results or other figures for either company.
Corteva completed the separation of its seed operating segment on October 1, 2026.
The spin-off was a pro rata distribution of Vylor shares to Corteva holders of record as of September 24, 2026.
Vylor is expected to trade on the NYSE under the symbol VYLR starting October 1, 2026.
The filing contains no financial figures for either company.
First Merchants announced on October 1, 2026 that CEO Mark Hardwick will retire at the end of 2026 after 29 years with the bank. The Board named President Mike Stewart, who has been with the bank for more than 18 years, to become President and CEO effective January 1, 2027, as part of the executive succession plan. The filing reports no new compensation arrangements for Stewart beyond existing ones, and it discloses no change to financial results.
Mark Hardwick, CEO, to retire; retirement effective January 1, 2027 per the 8-K
Mike Stewart, current First Merchants Bank President with more than 18 years at the bank, to become President and CEO effective January 1, 2027
Stewart's background is incorporated by reference from the April 3, 2026 proxy statement; no new compensation arrangements were entered into per the filing
Aptera Motors said it now estimates it needs about $25 million to reach start of production, down from $40 million to $45 million, and about $115 million for its full high-volume plan, down from $180 million to $205 million. The company attributes the lower estimates mainly to its partnership with Shanghai Launch Automotive Technology, but all estimates depend on obtaining financing on acceptable terms and on a timely basis.
Start of production estimate: about $25 million, down from $40 million to $45 million (a reduction of about 38% to 44%)
Full-plan estimate: about $115 million, down from $180 million to $205 million; about $65 million to reach 500 vehicles per month
First 40 production vehicles planned to begin building by end of 2026, with initial customer deliveries in early 2027, subject to financing
USA Rare Earth announced that its previously disclosed CEO succession is complete, with Thras Moraitis, formerly President, assuming the CEO role. The company also reorganized operations into three business units, with Moraitis heading Upstream, and a CEO letter to employees was distributed the same day.
Thras Moraitis assumed the CEO position, announced October 1, 2026; Barbara Humpton's departure as CEO is referenced in the release.
Operations are organized into three business units: Upstream (Moraitis), Midstream (Chaitan Kansal) and Downstream (David Bushi).
The filing does not include financial results, guidance or deal terms; the pending Carester transaction is mentioned without new figures.
Veritone agreed on September 30, 2026 to sell 20,000,000 shares of common stock to purchasers in a registered direct offering, with expected gross proceeds of $15.0 million before offering expenses. The company plans to use the net proceeds, together with existing cash, to repay or restructure part of its convertible debt and for working capital, and the forward-looking statements cite its 1.75% convertible senior notes due November 2026. The new shares add to the existing share count, while the filing says the proceeds are intended to address debt maturing later this year.
Issuance of 20,000,000 shares of common stock at $0.001 par value under an effective Form S-3 shelf registration
Expected gross proceeds of $15.0 million before offering expenses
Closing expected on or about October 2, 2026, subject to customary closing conditions
Proceeds intended to repay or restructure part of convertible debt, including 1.75% convertible senior notes due November 2026 referenced in the filing
Monte Rosa Therapeutics said its Phase 1 GFORCE-1 study of MRT-8102 in 108 obese subjects with elevated cardiovascular risk showed reductions in several inflammation and plaque-related markers, with no serious adverse events reported. The filing does not include revenue, earnings or guidance, and the results come from an early-stage study. The company plans to start several Phase 2 studies, with timing running from late 2026 to the first half of 2027.
GFORCE-1 enrolled 108 subjects, randomized to MRT-8102 at 5 mg, 20 mg or 40 mg once daily, or placebo, with 4 weeks of dosing and 4 weeks of follow-up.
NEK7 degradation had a median reduction of approximately 80% to 90% across all three dose levels.
Treatment-emergent adverse events occurred in 33% of MRT-8102 participants and 30% of placebo participants; no serious adverse events were reported.
Median lipoprotein(a) fell 24%; GFORCE-2 is expected to start in H1 2027 and GEMINI-1 in Q4 2026 or Q1 2027.
Foghorn Therapeutics and Eli Lilly decided not to advance the FHD-909 Phase 1 trial into its expansion phase, and the collaboration will not pursue further activities. Foghorn approved a strategic reprioritization and a workforce reduction of about 40%, leaving about 65 full-time employees, with aggregate charges of about $2.3 million mostly for severance and benefits. The company says the changes are expected to extend its cash runway into the second half of 2029.
Decision not to advance FHD-909 into expansion phase made September 25, 2026, after review of Phase 1 clinical data
Board approved reprioritization and workforce reduction on September 30, 2026; about 40% of current workforce affected, leaving about 65 full-time employees
Aggregate charges of approximately $2.3 million, expected to be incurred mainly in the fourth quarter of 2026
Press release says changes are expected to extend cash runway into the second half of 2029
Innovative Industrial Properties, through a subsidiary, agreed on September 28, 2026 to increase a mezzanine loan to IQHQ affiliates by $267.0 million, bringing the maximum principal to $400.0 million, with $245.0 million provided by the company. The loan supports the Alewife Park life science campus in Cambridge, Massachusetts, and the company said in its press release it expects the investment to add to earnings and increase its life science exposure.
Company subsidiary provides up to $245.0 million under Note B; about $111.0 million was funded at closing to repay a $85.0 million bridge loan
Remaining about $134 million is expected to be funded through the fourth quarter of 2027, subject to conditions
Interest rate is the greater of 14% or a benchmark plus a 9.0% spread; press release expects about 15.8% over the loan term
Maturity extended to February 9, 2028, with a second one-year extension option; company may also buy up to $155 million of another lender's notes
National Fuel Gas Company completed its acquisition of CenterPoint Energy's Ohio natural gas utility, Vectren Energy Delivery of Ohio, on October 1, 2026, paying $1.42 billion in cash and a $1.20 billion promissory note to the seller. The note bears 6.5% interest, matures September 30, 2027, and carries covenants including a debt-to-capitalization ceiling of 0.65. The company says the deal adds about 335,000 customers and doubles its utility rate base, but the filing does not quantify the earnings effect.
Purchase price of $2.62 billion: $1.42 billion in cash plus a $1.20 billion promissory note issued to the seller
Seller note carries a 6.5% rate and matures September 30, 2027; covenants include a debt-to-capitalization ratio of no more than 0.65
Acquired utility serves about 335,000 customers in 16 counties near Dayton, Ohio, and about 200 employees are joining the company
CenterPoint Energy completed the sale of Vectren Energy Delivery of Ohio, its Ohio natural gas distribution business, to National Fuel Gas Company on October 1, 2026, for $2.62 billion, subject to adjustments. The price includes $1.42 billion in cash paid at closing and a $1.20 billion promissory note from the buyer, which CenterPoint will hold as a seller note at 6.50% interest. CEO Jason Wells said the proceeds will help fund the company's $66.7 billion, 10-year capital plan.
Sale closed October 1, 2026; buyer is National Fuel Gas Company (NYSE: NFG)
Purchase price of $2.62 billion: $1.42 billion in cash plus a $1.20 billion promissory note, subject to adjustments
Seller note bears 6.50% interest and matures September 30, 2027
Business includes about 5,900 miles of gas pipeline serving about 335,000 metered customers in West Central Ohio
American Vanguard appointed Matthew Horwath as Chief Financial Officer effective October 1, 2026, succeeding David Johnson, who moved to Chief Accounting Officer as part of a planned leadership transition. Horwath's approved pay includes a $450,000 base salary, a 60% target bonus, and equity awards. The filing reports no financial results, so the change mainly affects who leads the finance function.
Matthew Horwath, age 43, becomes CFO effective October 1, 2026; he previously was CFO of FARO Technologies and of Kustom US, Inc.
Horwath's compensation includes a $450,000 annual base salary, a 60% target annual bonus, an option on 150,000 shares, and 100,000 restricted shares.
David Johnson serves as Chief Accounting Officer through the last day of the month the 2026 Form 10-K is filed (expected March 2027), then in a non-executive role through September 30, 2027.
Johnson's transition agreement provides severance of 1.5 times his salary and average bonus if his employment ends without cause or for good reason, subject to a release of claims.
VisionWave and Sadot Group closed a Joint Venture and Operating Agreement on September 30, 2026, creating CMJV, a 50/50 vehicle that holds VisionWave's rights in C.M. Composite Materials, including about $7.81 million of advances to CM. Sadot committed to fund an equal $7,814,323 in cash over time, but the planned 51% CM acquisition remains conditional on a Belrise joint venture that has not been satisfied or waived, and VisionWave does not currently own any CM equity.
On September 30, 2026, VisionWave, Sadot Group and CMJV LLC signed the JV Agreement; the joint venture closed the same day.
VisionWave contributed its CM rights and about $7.81 million of advances to CMJV for 7,814,323 membership units; Sadot committed $7,814,323 in cash.
Sadot must fund its commitment in tranches, with $3.0 million due by December 30, 2026, and the full amount by September 30, 2027.
The Belrise Condition is unsatisfied; the outside closing date was extended to December 31, 2026, and VisionWave received 250,000 Sadot common shares.
On September 30, 2026, Sadot Group entered a joint venture agreement with VisionWave Holdings and formed CMJV LLC, a 50/50 vehicle tied to C.M. Composite Materials, an Israeli composites maker, and issued 250,000 common shares to VisionWave as an entry premium. The company must fund a capital commitment equal to $7,814,323 in tranches over twelve months, but the acquisition of C.M. has not closed and its key closing condition remains unmet, so the company's interest could be reduced if it does not fund in full.
The company must fund $7,814,323 in cash to CMJV in tranches, with a minimum of $3.0 million by December 30, 2026 and the full amount by September 30, 2027.
The 250,000 shares issued to VisionWave were about 17.2% of the 1,457,589 shares outstanding as of September 29, 2026.
The Belrise Condition has not been satisfied or waived; the outside closing date for the C.M. acquisition was extended to December 31, 2026.
Director Haggai Ravid sits on the VisionWave board; the company's other directors approved the transactions after disclosure of his relationship.
Magnolia Oil & Gas provided an interim update after closing its acquisition of WildFire Energy, reporting approximately $1.9 billion of net debt at the end of the third quarter, lower than expected. The company also issued fourth-quarter 2026 production, capital spending and cost guidance for the first full quarter including WildFire, and said it expects one-time transaction and integration costs of approximately $65 to $75 million in the third quarter.
Net debt of approximately $1.9 billion at end of Q3 2026; leverage below 1.0x net debt to 2027E EBITDA at current strip prices
Q4 2026 guidance: production of 159 to 161 Mboe/d (49% to 50% oil) and D&C capital spending of approximately $235 million
One-time transaction and integration costs of approximately $65 to $75 million expected in Q3 2026
Purchased approximately 2.3 million shares in Q3 2026; about 267 million shares outstanding at quarter-end
Inseego closed its acquisition of Nokia's Fixed Wireless Access business on October 1, 2026, issuing Nokia 1,163,693 shares, warrants and assumed liabilities as consideration, and Nokia made a $10 million cash investment in Inseego. Inseego says the deal is expected to approximately double its revenue, but the filing gives no revenue or profit figures, and Nokia's stake of about 11% plus warrants dilutes existing shareholders.
Acquisition completed October 1, 2026; first announced April 30, 2026.
Inseego issued 1,163,693 shares and Consideration Warrants to Nokia and assumed certain FWA Business liabilities.
Nokia received about 1.9 million shares (about 11% ownership) and warrants for up to about 0.8 million shares at $4.26 per share.
Nokia will pay Inseego a further $10 million in cash by October 15, 2026; about 250 people associated with the business will support Inseego's operations.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.